(Beijing Comprehensive News) Chinese Enterprise Kangxino Bio said that an inhaled coronary vaccine developed by the company has been consent to the National Drug Administration of China as an emergency use for enhanced needles.
Comprehensive Beijing Youth Daily and Reuters reported that Kanghino issued a announcement on Sunday (4th) to announce the above news.
Kangshino's inhaled adenovirus carrier coronary vaccine was approved by the China Drug Administration of Drug Administration in March 2021. The indication was the disease caused by the prevention of coronary virus infection.
It is reported that inhaling crown disease vaccines can efficiently stimulate mucous membrane immunity, body fluid immune and cellular immunity triple protection.
Kangxino said that after the vaccine was approved for emergency use, if the relevant state departments were purchased and used on their procurement, it would have a certain positive impact on the company's performance.
However, Kangxino also said that there have been nine vaccines in China so far have been approved by the National Drug Administration for listing or emergency use. Three of them have been included in the World Health Organization.In the clinical trial stage, even if the company's products are included in emergency use, future market sales will still face more intense competition.
Lizhu Pharmaceutical Group issued a announcement last Friday (2nd) that the coronary vaccine developed by the company has been approved by the China National Drug Administration as an urgent use of needles.
Kangshino said when it is not sure when the company's inhaled coronary vaccine can be listed because it still needs additional administrative approval.
